EFFECT OF TRANEXAMIC ACID ON PLATELET REQUIREMENTS IN THROMBOCYTOPENIC PATIENTS

氨甲环酸对血小板减少症患者血小板需求的影响

• 批准号: 4691958
• 负责人: W A FRICKE
• 金额: --
• 依托单位: CLINICAL CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/4691958
• 关键词: antifibrinolytic agents; fibrinolytic therapy; hemorrhagic thrombocythemia; human subject; platelet transfusion; thrombocytopenia

We propose to study the benefit of oral antifibrinolytic therapy with tranexamic acid in thrombocytopenic patients with platelet counts of less than 20,000/microliter. These patients are at significant risk for bleeding, and may suffer epistaxis, oral, GI, GU or CNS hemorrhage. Currently, these patients are treated with platelet transfusiions in order to minimize this bleeding risk. However, such transfusions are not without morbidity: hepatitis, alloimmunization, allergic and febrile transfusion reactions, and volume overload may all result from platelet transfusions. It is also logistically difficult to give platelets to outpatients, and in many areas of the U.S. platelets for transfusion are not available. Moreover, such transfusions are expensive, and patients requiring large numbers of platelets may tax the ability of procurement programs to provide them. Antifibrinolytic therapy has been shwon to be of proven efficacy in some clinical situations associated with bleeding. We hope to establish that thrombocytopenic patients will benefit from antifibrinolytic therapy by having fewer bleeding episodes and requiring fewer transfusions.

我们建议研究口服抗纤溶治疗的益处 氨甲环酸在血小板减少症患者中的应用 超过20,000/微升。这些患者面临着极大的风险 出血，可出现鼻出血、口腔出血、消化道出血、胃肠道出血或中枢神经系统出血。 目前，这些患者正在按顺序接受血小板输注。 将出血风险降至最低。然而，这种输血并不是没有的 发病率：肝炎、异体免疫、过敏和发烧输血 反应和容量超载都可能是由血小板输注引起的。 向门诊患者提供血小板在后勤上也是困难的，而且在 美国许多地区的血小板无法用于输血。 此外，这种输血费用很高，患者需要大量的 血小板的数量可能会影响采购计划提供 他们。抗纤溶治疗已被证明在 与出血相关的一些临床症状。我们希望建立 血小板减少的患者将从抗纤溶治疗中受益 通过减少出血和需要输血的次数。